Dithiocarbamate-based coordination compounds as potent proteasome inhibitors in human cancer cells

Author(s): Daniela Buac, Sara Schmitt, George Ventro, Fathima Rani Kona, Q. Ping Dou

Journal Name: Mini-Reviews in Medicinal Chemistry

Volume 12 , Issue 12 , 2012

Become EABM
Become Reviewer
Call for Editor


Dithiocarbamates are a class of metal-chelating compounds with various applications in medicine. They have been used for the treatment of bacterial and fungal infections, possible treatment of AIDS, and most recently cancer. Their anti-tumor effects can in part be attributed to their ability to complex tumor cellular copper, leading to binding to and inhibition of the proteasome and in turn initiating tumor cell-specific apoptosis. Current chemotherapeutic agents are highly toxic and therefore their efficacy in the eradication of tumors is greatly limited. As a result many scientists have joined the quest for novel targeted therapies in hopes of reducing toxicity while maximizing potency and proteasome inhibition has become an attractive therapy in this regard. Here we discuss the origins, mechanism, and evolution of dithiocarbamates as potent proteasome inhibitors and therefore anti-cancer agents.

Keywords: Cancer therapy, Ubiquitin-Proteasome System, Apoptosis, Metal Complexes, Disulfiram, Antabuse, Proteasome inhibitors, UPS inhibitors.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2012
Published on: 04 September, 2012
Page: [1193 - 1201]
Pages: 9
DOI: 10.2174/138955712802762040
Price: $65

Article Metrics

PDF: 49